title: Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
abstract: Angiogenesis, the growth of new blood vessels from preexisting ones, is a necessary component of embryogenesis, wound healing, and the proliferative phase of the female reproductive cycle. Angiogenesis also plays a critical role in important pathologic processes such as cancer and cardiovascular complications. In addition, clinical, laboratory, and pharmacologic evidence has shown a link between angiogenesis, coagulation, hemostasis, and thrombosis in the settings of these pathologies. Recent studies in our laboratory revealed that thrombin has a significant stimulatory effect on angiogenesis. This effect of thrombin is independent of fibrin formation and can be attributed mainly to the activation of protease-activated receptor-1 (PAR-1). PAR-1 is widely expressed in vascular cells and is involved in cardiovascular complications such as atherosclerosis, restenosis, and neointimal formation. It is also expressed in many cancer cells contributing to induction of tumor growth and metastasis. In this review, we will summarize our present-day understanding of the role of thrombin and PAR-1 in angiogenesis and the potential therapeutic utility of targeting PAR-1 in angiogenesis-related disease, such as atherosclerosis, restenosis, and cancer.
authors.affiliation: Department of Pharmacology, Medical School, University of Patras, Patras, Greece. ntsopan@med.upatras.gr
authors.forename: Nikos E
authors.initials: NE
authors.lastname: Tsopanoglou
authors.forename: Michael E
authors.initials: ME
authors.lastname: Maragoudakis
mesh_terms: D000818:Animals; D017209:Apoptosis; D001777:Blood Coagulation; D001808:Blood Vessels; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D044463:Receptor, PAR-1 / Q000378:metabolism*; D013917:Thrombin / Q000378:metabolism; D013925:Thromboplastin / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors
chemical_list: D044463:Receptor, PAR-1; D013925:Thromboplastin; D013917:Thrombin; D010975:Platelet Aggregation Inhibitors